SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al.EULAR recommendations for the management of systemic lupus erythematosus: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.Ann Rheum Dis2008;67:195205.
  • 2
    Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA.Definition and treatment of lupus flares measured by the BILAG index.Rheumatology (Oxford)2003;42:13729.
  • 3
    Mirzayan MJ, Schmidt RE, Witte T.Prognostic parameters for flare in systemic lupus erythematosus.Rheumatology (Oxford)2000;39:13169.
  • 4
    Petri M, Buyon J, Kim M.Classification and definition of major flares in SLE clinical trials.Lupus1999;8:68591.
  • 5
    Petri M, Singh S, Tesfasyone H, Malik A.Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study.J Rheumatol2009;36:247680.
  • 6
    Ho A, Barr SA, Magder LC, Petri M.A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.Arthritis Rheum2001;44:23507.
  • 7
    Ho A, Magder LS, Barr SG, Petri M.Decreases in anti–double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus.Arthritis Rheum2001;44:23429.
  • 8
    Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al, and Members of the British Isles Lupus Assessment Group (BILAG).Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus.Q J Med1988;69:92737.
  • 9
    Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG.Measurement of increases in anti–double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study.Arthritis Rheum1990;33:63443.
  • 10
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE.Derivation of the SLEDAI: a disease activity index for lupus patients.Arthritis Rheum1992;35:63040.
  • 11
    Gladman DD, Ibanez D, Urowitz MB.Systemic Lupus Erythematosus Disease Activity Index 2000.J Rheumatol2002;29:28891.
  • 12
    Nikpour M, Urowitz MB, Ibanez D, Gladman DD.Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus.Arthritis Rheum2009;61:11528.
  • 13
    Ibanez D, Gladman DD, Urowitz MB.Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.J Rheumatol2005;32:8247.
  • 14
    Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al.Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.Arthritis Rheum2002;46:9951002.
  • 15
    Borowoy AM, Pope JE, Silverman E, Fortin PR, Pineau C, Smith CD, et al.Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 face of lupus cohort.Semin Arthritis Rheum2012;42:17985.
  • 16
    Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al, for the OC-SELENA Trial.Combined oral contraceptives in women with systemic lupus erythematosus.N Engl J Med2005;353:25508.
  • 17
    Bauer JW, Petri M, Batliwalla FM, Koeuth T, Wilson J, Slattery C, et al.Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study.Arthritis Rheum2009;60:3098107.
  • 18
    Ng KP, Manson JJ, Rahman A, Isenberg DA.Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.Arthritis Rheum2006;55:9004.
  • 19
    Canadian Hydroxychloroquine Study Group.A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.N Engl J Med1991;324:1504.
  • 20
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, et al.The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.Arthritis Rheum2006;54:362332.
  • 21
    Edwards CJ, Lian TY, Badsha H, Teh CL, Arden N, Chng HH.Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome.Lupus2003;12:6726.
  • 22
    Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA.Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus—a 5-yr prospective study.Rheumatology (Oxford)2004;43:103944.
  • 23
    Zhu TY, Tam LS, Lee VW, Lee KK, Li EK.The impact of flare on disease costs of patients with systemic lupus erythematosus.Arthritis Rheum2009;61:115967.
  • 24
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al, for the BLISS-76 Study Group.A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.Arthritis Rheum2011;63:391830.
  • 25
    Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al, for the BLISS-52 Study Group.Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.Lancet2011;377:72131.
  • 26
    Isenberg DA, Gordon C, BILAG Group, British Isles Lupus Assessment Group.From BILAG to BLIPS—disease activity assessment in lupus past, present and future.Lupus2000;9:6514.
  • 27
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al.The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus.Arthritis Rheum1996;39:3639.
  • 28
    Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter].Arthritis Rheum1997;40:1725.
  • 29
    Cheema GS, Roschke V, Hilbert DM, Stohl W.Elevated serum B lymphocyte stimulator levels in patients with systemic immune– based rheumatic diseases.Arthritis Rheum2001;44:13139.
  • 30
    Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al.Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.Arthritis Rheum2008;58:24539.
  • 31
    Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al.A role for B lymphocyte stimulator in systemic lupus erythematosus.J Immunol2001;66:610.
  • 32
    Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al, on behalf of the BLISS-52 and BLISS-76 Study Groups.Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.Arthritis Rheum2012;64:232837.
  • 33
    Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al, the Canadian Hydroxychloroquine Study Group.A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus.Lupus1998;7:805.
  • 34
    Costedoat-Chalumeau N, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F, et al, on behalf of Group PLUS.Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).Ann Rheum Dis2013. E-pub ahead of print.